Objectives Randomised-controlled trials have recently proven the efficacy of the interleukin (IL)-6 receptor antagonist tocilizumab (TCZ) in giant cell arteritis (GCA). However, the mechanism of action of IL-6 blockade in this disease is unknown. Moreover, the role of regulatory T (Treg) cells in the pathogenesis of GCA remains underexplored. Given the plasticity of Tregs and the importance of IL-6 in their biology, we hypothesised that TCZ might modulate the Treg response in GCA. We therefore characterised the Treg compartment of patients with GCA treated with TCZ.
INTRODUCTION
Giant cell arteritis (GCA) is the most frequent primary vasculitis in Western countries. 1 The main histopathological feature of the disease comprises a granulomatous inflammatory process rich in CD4 + T cells and macrophages that involves largesized and medium-sized arteries. 1 Most patients develop relapsing courses despite prolonged treatments with corticosteroid (CS), which invariably lead to drug-related toxicity. 2 Agents that maintain disease remission and spare the use of CS are therefore the greatest unmet need for this patient population. [3] [4] [5] [6] An imbalance among CD4 + T helper (Th)1, Th17 and regulatory T (Treg) cells is thought to contribute to the pathogenesis of GCA. [7] [8] [9] Patients with new-onset disease demonstrate Th1 and Th17 cell infiltrates in their arteries and an expansion of these cell subsets in peripheral blood. [7] [8] [9] Conversely, decreased numbers of Tregs in the peripheral circulation are found in patients with GCA, regardless of the state of disease activity. 8 9 Although the Th17 axis is sensitive to CS treatment, [7] [8] [9] [10] some reports suggest that the abnormalities described in both the Th1 and Treg subsets are resistant to CS therapy, 7 8 thereby accounting for the high relapse rate in GCA following CS tapering.
The interleukin (IL)-6 pathway is a novel target in GCA. Patients with GCA demonstrate increased IL-6 RNA expression within inflamed arteries 11 12 and elevated IL-6 protein levels in the peripheral blood during active disease. 13 Recently, two randomised controlled trials showed that tocilizumab (TCZ), a monoclonal antibody against the IL-6 receptor (IL-6R), is effective in maintaining disease remission in absence of CS. 14 15 However, the mechanism of action of IL-6 signalling blockade in GCA remains unknown.
Considerable phenotypical and functional plasticity exists within the Treg and the Th17 cell subsets. 16 Th17 cells and Tregs develop from a common naive CD4 + T cell precursor under the influence of transforming growth factor-β (TGF-β). 17 In the presence of proinflammatory mediators (eg, IL-6 or IL-21), TGF-β-stimulated CD4 + T cells differentiate into Th17 cells, whereas in the absence of an inflammatory microenvironment these TGF-β-stimulated precursors are induced to become Tregs. 18 Furthermore, under specific circumstances, fully differentiated Tregs may lose their suppressive function and become IL-17-producing cells 16 (eg, 'pathogenic Tregs' 19 20 and exFoxp3 Th17 cells).
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One mechanism regulating the divergent fates between Tregs and Th17 cells involves the molecular antagonism of RAR-related orphan receptor (ROR) γt (RORC in humans) by Foxp3 through the domain encoded by the exon 2 of the FOXP3 gene. 22 Tregs that express a spliced variant of Foxp3 lacking exon 2 (Foxp3Δ2) are less suppressive, 23 and more likely to become IL-17 producing Tregs. Increased numbers of Foxp3Δ2 + Tregs have been reported in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. 24 It is not known, however, whether this abnormality is also present in patients with GCA. In addition, cells that express both Foxp3 and IL-17 have been detected in inflamed GCA arteries, 10 but whether this cell population is present in peripheral circulation, and most importantly, whether disease treatment reverts the pathogenic phenotype of those Tregs has been insufficiently studied.
We aimed to characterise the regulatory CD4 + T cell compartment in peripheral blood of patients with GCA and to investigate the effects of IL-6R blockade therapy with TCZ on the frequency, phenotype and function of those cells.
MATERIALS AND METHODS Study population
We evaluated 41 patients with GCA in a cross-sectional study. Patients with GCA were classified into one of three categories based on disease activity and treatment: active disease (aGCA, n=11), disease remission on CS monotherapy (rGCA-CS, n=19) and disease remission on TCZ therapy (rGCA-TCZ, n=11). Among the subjects with aGCA, three had new-onset disease and eight were sampled during a disease relapse. We also evaluated samples from 10 healthy controls (HCs). Upon diagnosis, all patients had been treated with CS according to the standard of care for GCA. 1 Patients in the TCZ group (rGCA-TCZ group) received their IL-6R blockade therapy because of relapsing disease or prohibitive CS-related toxicity during previous treatment courses. Once on TCZ, patients underwent a prednisone taper of variable rate, but generally faster than the standard of care in order to ameliorate or prevent CS-related toxicity. Other clinical information is provided in the online supplementary text.
Cell isolation, culture and flow cytometry
CD4
+ T cells were purified (>90% purity) from whole blood using RosetteSep CD4 + enrichment antibody cocktail (StemCell Technologies) according to manufacturer's instructions. Cells were labelled with Pacific Blue-conjugated anti-CD4, fluorescein isothiocyanate-conjugated anti-CD45RA, phycoerythrin (PE)-Cy7-conjugated anti-CCR4, PE-conjugated anti-CTLA4, allophycocyanin (APC)-Cy7-conjugated anti-IL-17A, PE-Cy7-conjugated anti-CD25, PE-conjugated anti-Ki67, APC-conjugated anti-CD161 (BioLegend); Alexa Fluor 488-conjugated anti-Foxp3 and Alexa Fluor 700-conjugated anti-Foxp3. Foxp3Δ2 was detected using clone PCH101 (eBiocience) that recognises the N-terminus portion of the protein and clone 150D (BioLegend) that recognises exon 2. 24 25 Data were acquired on a LSRFortessa cell analyser (BD biosciences) and analysed with FlowJo software. 
Treg suppression assays

RESULTS
Baseline characteristics of patients with GCA and HCs
The baseline characteristics of patients with GCA and HCs are shown in table 1. There were no significant differences among patient groups (aGCA, rGCA-TCZ and rGCA-CS) with regard to demographic features, disease type or disease duration. The mean daily dose of prednisone at the time of blood sampling was 15.7 mg in patients in the rGCA-CS group, 0.2 mg in patients in the rGCA-TCZ group and 8.0 mg in patients in the aGCA group (p=0.02). Patients in the rGCA-TCZ group had received TCZ for a median period of 18 months. The HCs were younger than the patients with GCA (mean age 59 years vs 72 years; p<0.01), but there were no other important differences.
TCZ increases the frequency of activated Tregs
We first measured the population of Tregs defined as CD4 + T cells expressing Foxp3 and found no significant differences among groups (see online supplementary figure S1A, B). We then classified Tregs into three functionally distinct subpopulations based on the level of expression of Foxp3 and CD45RA: 26 figure  1A ). We observed that the mean per cent of aTregs was significantly greater in patients in the rGCA-TCZ group (1.3% (SD 0.9)) compared with patients in the rGCA-CS group (0.6% (SD 0.4)) ( p<0.01) (figure 1B). There were no significant differences among groups in terms of rTregs and non-suppressive Foxp3 low cells (see online supplementary figure S2). The phenotype of cellular activation observed in Tregs derived from patients in the rGCA-TCZ group was then confirmed by measuring on all CD4 + Foxp3 + cells the expression of CCR4 and CTLA-4, markers of the most terminally differentiated activated effector Tregs [26] [27] [28] [29] [30] (figure 1B). The differences between patients in the rGCA-TCZ group and patients in the rGCA-CS group in terms of the numbers of aTregs, CD4 + Foxp3 + CCR4 + cells and CD4 + Foxp3 + CTLA-4 + cells remained statistically significant after analyses adjusted for age and CS dose. As expected, aTregs demonstrated higher expression of CD25, CCR4 and CTLA-4 when compared with rTregs and non-suppressive Foxp3 low cells ( figure 1C ). These findings demonstrate that in patients with GCA, remission maintenance with IL-6 blockade therapy is associated with increased Treg activation.
TCZ restores the impaired proliferative capacity of Tregs
Tregs are among the most actively replicating cells within the CD4 + T cell compartment, and impaired Treg proliferation has been implicated in the pathogenesis of autoimmunity. 31 Thus, we investigated the proliferative capacity of Tregs in patients with GCA and HCs by measuring the expression of Ki67, a figure 2A, B) . These differences persisted in CS dose-and ageadjusted analyses. The expression of Ki67 in CD4 + Foxp3
− T cells, however, did not differ significantly among groups (see online supplementary figure S3) . These results suggest that Treg proliferation is impaired in GCA and that TCZ, in contrast to CS, selectively restores the Treg replicative potential without influencing the proliferation of non-regulatory CD4 + T cells.
TCZ decreases the number of Foxp3Δ2 + Tregs
During Treg ontogeny, the exon 2 of Foxp3 directly inhibits key transcription factors that drive the Th17 cell differentiation programme. 22 32 Recently, less suppressive Tregs that disproportionately express Foxp3Δ2 have been reported in human autoimmune disease. 24 We therefore analysed the expression of full-length Foxp3 and Foxp3Δ2 in proliferating Tregs of patients with GCA and HCs ( figure 3A) . We observed that the mean per cent of Ki67 + Foxp3Δ2 + Tregs was not significantly different between patients in the rGCA-TCZ group (26.3% (SD 11.4)) and HCs (25.3% (SD 6.7)) ( p=0.88) (figure 3B). In contrast, patients in the rGCA-TCZ group demonstrated significantly lower numbers of Ki67 + Foxp3Δ2 + Tregs when compared with both, patients in the rGCA-CS group (54.9% (SD 21.4); p=0.03) and patients in the aGCA group (63.2% (SD 16.2); p=0.01) (figure 3B). These differences persisted in CS doseand age-adjusted analyses. These results demonstrate that the increased Foxp3Δ2 Treg expression seen in patients with GCA is not corrected by CS, but is abrogated upon IL-6 signalling inhibition with TCZ.
Foxp3Δ2 + Tregs coexpress CD161
It has been demonstrated that IL-6-stimulated Tregs may become IL-17 producing cells. 16 20 21 In addition, figure 3D ). The correlation between fulllength Foxp3 and CD25 and between Foxp3Δ2 and CD161 was equivalent across all groups (aGCA, rGCA-CS, rGCA-TCZ and HC) (see online supplementary figure S4 ). In summary, Foxp3Δ2-expressing Tregs demonstrated decreased coexpression of CD25 and increased coexpression of CD161, a phenotype that suggests the potential for IL-17 production.
TCZ reduces the population of IL-17-producing Tregs
Because our data showed that proliferating Tregs derived from patients with active disease preferentially expressed Foxp3Δ2, and these cells were also characterised by CD161 co-staining, we examined the Treg production of IL-17 (figure 4A). We found that the mean per cent (SD) of IL-17 + Tregs in aGCA, rGCA-CS, rGCA-TCZ and HC was 4.40% (1.29), 2.68% (1.36), 1.29% (1.69) and 1.94% (1.14), respectively (figure 4B). Whereas no significant differences in the numbers of IL-17 + Tregs existed between HCs and patients in the rGCA-TCZ group ( p=0.39), patients in the rGCA-TCZ group demonstrated significantly lower numbers of IL-17 + Tregs than patients in the aGCA group ( p<0.01) and a trend towards fewer of these cells compared with patients in the rGCA-CS group ( p=0.06). The differences among GCA groups persisted in CS dose-and age-adjusted analyses. In concordance with prior reports, 20 26 the main source of IL-17 within the Treg population of patients with active disease resided in the CD45RA
−
Foxp3
low non-suppressive cell subset ( figure 4C, D ). These results demonstrate that the IL-17-producing Treg + Foxp3 + T cells in patients with GCA (rGCA-TCZ, n=5; rGCA-CS, n=7; aGCA, n=5) and HC (n=5). Analysis: Student's t-test. Error bars represent means and SD. aGCA, active GCA; GCA, giant cell arteritis; rGCA-CS, GCA in remission on CS; rGCA-TCZ, GCA in remission on TCZ without or without CS; TCZ, tocilizumab. population is expanded in peripheral blood during periods of GCA activity, and that TCZ abrogates this abnormality more efficiently than do CS.
Treg function is impaired in GCA
Previous research has shown that IL-6 may decrease Treg function. 33 In patients with new-onset GCA, however, Tregs have been reported to be competent regardless of disease activity or CS treatment. 8 To investigate whether patients with GCA in our cohort had normal or impaired Treg function and to examine whether IL-6 blockade influenced this function, we performed suppression assays coculturing CD4 + CD25 − conventional T cells and CD4 + CD25 + Tregs. The results showed no significant differences in Treg function among the GCA groups ( figure 5A, B) . However, Tregs derived from patients with GCA taken together demonstrated significantly impaired suppressive ability when compared with Tregs derived from HCs ( figure 5A, B 26 and found no significant differences among groups (see online supplementary figure S5).
DISCUSSION
We sought to characterise the peripheral Treg compartment in GCA and to evaluate whether IL-6R blockade was associated with modulation of the Treg response. Our results showed that patients with active disease have a defective and likely pathogenic Treg population that demonstrates decreased proliferation, overexpression of Foxp3Δ2 and increased IL-17 production. In addition, our study revealed a mechanism by which IL-6 signalling inhibition may exert its therapeutic effects in GCA. Foxp3 largely controls the phenotype and function of Tregs. 34 Three variants of Foxp3 have been described, a fulllength and two spliced forms (Foxp3Δ2 and Foxp3 lacking exon 2 and 7 (Foxp3Δ2Δ7)). 35 36 Although the regulation and function of Foxp3Δ2 and Foxp3Δ2Δ7 are poorly understood, 35 36 exon 2 is known to encode a repression domain that blocks the activity of the transcription factors RORγt (RORC in humans) and RORα, which are involved in the differentiation of CD4 + cells towards the Th17 phenotype. 22 32 37 Foxp3Δ2 is regarded as a hypofunctional isoform of Foxp3 23 32 and increased expression of this spliced variant has been reported as a mechanism of immune dysregulation in ANCA-associated vasculitis. 24 Herein, we demonstrate for the first time that Tregs in patients with GCA preferentially express Foxp3Δ2 over full-length Foxp3. Moreover, we show that Foxp3Δ2 Tregs are often CD161 high CD25 low , which suggests potential for IL-17 production. 20 We therefore predict that Foxp3Δ2 Tregs in GCA lose their suppressive function, and themselves become pathogenic as a source of IL-17.
The functional plasticity of Tregs is highly dependent on the surrounding microenvironment, 17 18 20 and the stability of Tregs is thought to play a role in the pathogenesis of inflammatory disorders. 20 21 38 39 IL-17-producing Tregs have been detected in inflamed tissues of patients with autoimmune conditions such as rheumatoid arthritis, in which IL-6 may induce Tregs to become IL-17 + cells. 20 In some cases, IL-17-producing Tregs seem to 'relax' their suppressive function, 20 but in others, they retain full regulatory capacity. 20 40 41 Of note, IL-17 + Foxp3 + cells have also been found infiltrating arteries of patients with GCA. 10 However, their functional characterisation, contribution to disease pathogenesis and response to treatment have not been fully elucidated. Here we show that IL-17-producing Tregs are also present in peripheral blood of patients with GCA during periods of disease activity, and that their expansion normalises following IL-6R blockade therapy. In accordance to prior reports, we found that IL-17-producing Tregs in GCA also express other markers commonly associated with the Th17 lineage (eg, CD161) 20 and reside within the CD45RA − Foxp3 low non-suppressive cell subset. 20 26 Because we observed that TCZ led to pronounced reduction of both, Foxp3Δ2 and IL-17 expression, we speculate that by a yet undefined mechanism, IL-6 promotes the transcription of Foxp3Δ2 in Tregs with subsequent polarisation of these cells towards the Th17 phenotype. The function of IL17-producing Tregs and Foxp3Δ2 Tregs in GCA remains to be determined.
The reasons why Samson et al 8 found reduced frequencies of functional Tregs in patients with GCA and we did not are not apparent. Possible explanations include differences in the methods used to isolate Tregs as well as differences in the characteristics of the populations analysed. Our cohort was composed of patients with GCA with long disease duration and prolonged CS exposure (mean 27 months). In contrast, the cohort studied by Samson et al was comprised of newly diagnosed patients, whose CS treatment was relatively short (mean 3.4 months). It is possible that early phases of the disease are characterised by decreased numbers of competent Tregs, which tend to normalise in number over time, but become functionally deficient under the influence of chronic inflammatory stimuli or prolonged CS exposures.
Tregs from patients with GCA undergoing TCZ therapy did not demonstrate enhanced ability to suppress the proliferation of conventional T cells despite the increased expression of effector molecules (eg, CTLA-4). Although this apparent discrepancy could represent a type II error, other possibilities also exist. First, an augmented regulatory response can be achieved not only by increasing Treg function, but also by increasing the trafficking of Tregs to the sites of inflammation. CCR4 is involved in Treg migration 42 and has been shown to direct Tregs into cardiovascular allografts, the allergic lung and certain tumours. [43] [44] [45] It could be hypothesised that a highly proliferative Treg compartment that expresses CCR4 may form the basis for increased Treg cell migration into inflamed arteries. In addition, other important in vivo mechanisms by which Tregs exert their function (eg, through CTLA-4 competition with CD28 for binding to CD80/86) 30 46 could not be assessed in the functional assay used.
Two randomised controlled trials have recently demonstrated that TCZ is effective in maintaining disease remission and sparing CS in GCA. 14 15 Our findings complement the results of these trials and provide a pathophysiological rationale for the use of IL-6 blockade therapy in this disease. In addition, given that several of the Treg abnormalities observed in patients with active disease were not fully reversed upon treatment with CS monotherapy, our results may also provide insight into the reason why the great majority of CS-treated patients relapse upon CS dose reduction.
In summary, we found that GCA is associated with marked abnormalities in the peripheral Treg compartment. In addition, we demonstrated that unlike CS treatment, TCZ-therapy not only abrogated the pathogenic Treg phenotype seen during periods of disease activity, but also increased Treg activation, proliferation and terminal differentiation. Limitations of our study include its cross-sectional nature and the relatively small sample size; therefore, larger studies that include longitudinal follow-up of patients with new-onset GCA treated with TCZ will be required to continue to improve our understanding of the beneficial effects of blocking IL-6 in this disorder.
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